1. Top
  2. IR Information
  3. News Releases

News Releasess

May.30,2017 Dr. Matsuzaki, the head of Drug Design Lab, gave a poster presentation titled “True Landscape of Drug-Protein Binding” at JCUP VIII, an annual science meeting held by OpenEye Scientific Software Inc.
Sept.20,2016 New York Medical College and Interprotein Announce Research Partnership Agreement on Drug Discovery Research for small molecule PPI Inhibitors
Apr.25,2016 Interprotein Corporation and A.I. Squared, Inc. Sign a Joint Research and Development AI Drug Discovery Agreement
Nov.19,2015 Ipsen and Interprotein enter into a research collaboration for novel peptides in endocrinology
Dec.15,2014 Adoption of the subject that Interprotein has applied as a subject for A-STEP
Mar.20,2014 Participation of Interprotein in the space experiment for generation of high-quality protein crystals in "Kibo"
Nov.25,2013 Adoption of conformationally-constrained peptide (MicroAntibody) binding to vascular endothelial growth factor (VEGF) as a subject for A-STEP
Nov.16,2013 Dr.Takao Matsuzaki,Head of Drug Design Lab gave a lecture on ASDD 2013-BIT?fs 1st Annual Symposium of Drug Designology 2013.
Sep.2,2013 The first result of assessment of small molecule protein-protein interaction (PPI) inhibitors identified by the collaborative research between RaQualia and Interprotein
Apr.19,2013 Agreement on molecular design of small molecule protein-protein interaction (PPI) inhibitor between Interprotein Corporation and Takeda Pharmaceutical Company Limited
Feb.1,2013 RaQualia and Interprotein Announce Collaborative Research Agreement on Drug Discovery Research for PPI Inhibitors
Jan.30,2013 Interprotein made a presentation at the BIO Asia 2013.
Dec.4,2012 Adoption of peptide VEGF inhibitor (micro antibody) program as a subject for A-STEP
Nov.22,2012 Result of Assessment of Small molecule Protein-Protein Interaction (PPI) inhibitors Designed by Interprotein Corporation
Nov.15,2012 Adoption of small molecule IL-6 inhibitor program of Interprotein as a subject for A-STEP
Mar.19,2012 Interviews with leading Life Sciences companies: Interprotein, By Venture Valuation
Nov.21,2011 Ajinomoto Pharmaceuticals Co., Ltd. and Interprotein Corporation Sign a Joint R&D and Commercialization Agreement
Sep.30,2010 Interprotein and LegoChem Biosciences Sign Collaboration Agreement to Develop VEGF Inhibitor to Treat Solid Tumors
Sep.27,2010 Collaboration Agreement on Drug Discovery Research between Interprotein Corporation and Ajinomoto Pharmaceuticals Co., Ltd.
Nov.25,2009 Interviews with leading Life Sciences companies: Interprotein, By Venture Valuation
Nov.21,2008 Adoption of Interprotein?fs VEGF project in Super Special Consortia for supporting the development of cutting-edge medical care
Feb.27,2007 Evotec and Interprotein Sign Collaboration Agreement to Develop Interleukin 6 Inhibitors to Treat Inflammatory Diseases
Jan.27,2006 Exclusive Patent Licensing of Degranulation Inhibiting Mechanism on Allergy-related Cells
Aug.9,2005 The announcement of Inter Cyto Nano Science and Dr. Jun Fujita, professor of the Kyoto University?Cagreed on a patent licensing of production yield improvement of recombinant protein